ANDA 207389, held by Invagen Pharms. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 207389 (Bupropion Hydrochloride), held by Invagen Pharms, was first approved by FDA on Sep 18, 2017, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 18, 2017 | Original application | Approved | None posted |
| Bupropion Hydrochloride75MG · tablet;oral | Bupropion Hydrochloride | Discontinued |
| Bupropion Hydrochloride100MG · tablet;oral | Bupropion Hydrochloride | Discontinued |
| Nov 6, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 8, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 8, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 29, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 18, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters